Get the Stockscreener App
3.83
2.54%
-0.10
Lantern Pharma Inc stock is traded at $3.83, with a volume of 56,244.
It is down -2.54% in the last 24 hours and down -13.93% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.93
Open:
$3.93
24h Volume:
56,244
Relative Volume:
0.31
Market Cap:
$41.36M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-2.1517
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
-11.14%
1M Performance:
-13.93%
6M Performance:
-0.26%
1Y Performance:
+1.06%
1-Day Range:
$3.81
$3.9473
1-Week Range:
$3.7411
$4.45
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.83 | 42.77M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN) - GlobeNewswire Inc.
Lantern Pharma Inc. At Decision Level — Rebound or Resistance2025 Buyback Activity & Comprehensive Market Scan Reports - beatles.ru
Does Lantern Pharma Inc. align with a passive investing strategyJuly 2025 Selloffs & Technical Pattern Recognition Alerts - beatles.ru
Sentiment analysis tools applied to Lantern Pharma Inc.July 2025 Gainers & Weekly Breakout Opportunity Watchlist - Newser
How liquid is Lantern Pharma Inc. stockJuly 2025 Volume & Weekly Return Optimization Plans - خودرو بانک
Can Lantern Pharma Inc. disrupt its industryQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - خودرو بانک
Can Lantern Pharma Inc. grow without dilution2025 Retail Activity & Stock Portfolio Risk Management - 더경남뉴스
Is Lantern Pharma Inc. stock trending bullishPortfolio Performance Summary & Verified Momentum Stock Watchlist - خودرو بانک
Lantern Pharma Inc. stock volume spike explainedTrade Risk Assessment & AI Powered Market Entry Ideas - Newser
Lantern Pharma Inc. stock chart pattern explained2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Can Lantern Pharma Inc. lead its sector in growthQuarterly Trade Summary & AI Enhanced Execution Alerts - خودرو بانک
Hoth Therapeutics shares fall 2.24% premarket after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
How sentiment analysis helps forecast Lantern Pharma Inc.Portfolio Return Report & Growth-Oriented Investment Plans - Newser
Using data tools to time your Lantern Pharma Inc. exitJuly 2025 Reactions & High Accuracy Investment Signals - Newser
Hoth Therapeutics shares fall 1.49% after-hours after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial - The Globe and Mail
Lantern Pharma shares fall 1.52% intraday after FDA meeting and Hoth Therapeutics partnership. - AInvest
AI-Driven Drug Development: Hoth Therapeutics and Lantern Pharma’s Strategic Partnership to Revolutionize CNS Therapies - AInvest
Lantern Pharma's PredictBBB.ai Platform to Drive Next-Gen Drug Development with Hoth Therapeutics Partnership - AInvest
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development - WV News
Detecting support and resistance levels for Lantern Pharma Inc.CEO Change & Smart Swing Trading Alerts - Newser
What data driven models say about Lantern Pharma Inc.’s future2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will breakout in Lantern Pharma Inc. lead to full recoveryBear Alert & Fast Moving Stock Trade Plans - Newser
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial of AI-Discovered Therapy - citybuzz -
Automated trading signals detected on Lantern Pharma Inc.Market Movement Recap & Detailed Earnings Play Alerts - Newser
Lantern Pharma announces completion of Type C meeting with FDA - MSN
Lantern Pharma receives FDA feedback on pediatric brain cancer trial - Investing.com
Lantern Pharma Completes FDA Type C Meeting, Advances Pediatric CNS Cancer Trial with FDA Guidance - AInvest
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial - Business Wire
Top chart patterns to watch in Lantern Pharma Inc.July 2025 Review & Daily Chart Pattern Signals - Newser
What is Lantern Pharma Inc.’s book value per shareWeekly Profit Report & Risk Controlled Daily Trade Plans - خودرو بانک
How high can Lantern Pharma Inc. stock goMarket Sentiment Summary & Daily Profit Focused Stock Screening - Newser
Market reaction to Lantern Pharma Inc.’s recent newsWeekly Stock Analysis & Risk Managed Investment Strategies - Newser
How to integrate Lantern Pharma Inc. into portfolio analysis toolsJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - Newser
Will Lantern Pharma Inc. price bounce be sustainableWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
What machine learning models say about Lantern Pharma Inc.Fed Meeting & Accurate Entry/Exit Alerts - Newser
Does Lantern Pharma Inc. show high probability of reboundJuly 2025 Levels & Weekly High Return Opportunities - Newser
Is Lantern Pharma Inc. a cyclical or defensive stock2025 Market Trends & Weekly Market Pulse Alerts - خودرو بانک
Custom strategy builders for tracking Lantern Pharma Inc.Weekly Trend Summary & Target Return Focused Picks - Newser
Is Lantern Pharma Inc. vulnerable to short sellersBond Market & Low Volatility Stock Recommendations - خودرو بانک
Aug Rallies: What is the next catalyst for Lantern Pharma Inc.Market Volume Report & Safe Entry Trade Reports - خودرو بانک
Using Bollinger Bands to evaluate Lantern Pharma Inc.M&A Rumor & Stock Portfolio Risk Control - Newser
Can Lantern Pharma Inc. reach resistance levels soon2025 Market Trends & Fast Gaining Stock Strategy Reports - خودرو بانک
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):